INMB Inmune Bio, Inc.
FY2024 10-K
Inmune Bio, Inc. (INMB) filed its fiscal year 2024 10-K annual report with the SEC on Mar 27, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2024 10-K
Business Overview
- • Core business: Develops innate immune system-targeted biologic therapies for cancer, neurodegenerative diseases, and rare pediatric disorders
- • NEW emphasis: Added CORDStrom stem cell product for recessive dystrophic epidermolysis bullosa (RDEB), pivotal trial complete, plans BLA filing in US 2025-2026
Management Discussion & Analysis
- • Net loss $42.1M FY2024 vs $30.0M FY2023; cash $20.9M FY2024 vs $35.8M FY2023, cash burn increasing
- • R&D expense $33.2M FY2024 vs $20.3M FY2023, driven by DN-TNF Alzheimer’s $23.8M and INKmune/CORDStrom $4.6M
Risk Factors
- • Regulatory risk FDA approval delays or non-approval; potential loss of priority or accelerated review, impacting time-to-market for product candidates
- • Macroeconomic risk capital depletion risk; cash $20.9M as of Dec 31, 2024 vs $35.8M in 2023 with $42.1M net loss in 2024 risking going concern status
Financial SummaryXBRL
Revenue
$14,000
Net Income
-$42M
Operating Margin
-304535.7%
Net Margin
-300585.7%
ROE
-131.1%
Total Assets
$40M
EPS (Diluted)
$-2.11
Operating Cash Flow
-$33M
Source: XBRL data from Inmune Bio, Inc. FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Inmune Bio, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.